Every PMCPA ruling since 2005 — searchable and filterable by company, clause, and ABPI Code version.
Case Library Membership
Search free — but unlock advanced filters to find every case involving a specific company or clause.
Already a member? Sign in →
Case Library Membership
inc. VAT
inc. VAT · cancel any time
Secure payment via Stripe
Need access for your team?
Company licences available for compliance teams, medical affairs, and training programmes.
Get a team quote →1,930 cases found
An oncologist complained about “magnetic words” enclosed with an Arimidex mailing. The Panel said it was a promotional aid, not relevant to…
A MASTA rep sent an unapproved promotional email about Epaxal without prescribing info. Follow-up “training” pointed staff to an out-of-date Code and…
Roche’s Bondronat leavepiece was ruled misleading for indirect cross-trial graphs, exaggerated “renal safety reassurance” claims, and unclear interim poster data. Multiple Clause…
Novartis’ UK press release headline implied an overall survival benefit for Femara vs tamoxifen despite non-significant ITT results (p=0.08) and insufficient caveats…
Novo Nordisk-funded Times supplement included interview claims about liraglutide trial benefits before approval. Panel found public promotion, lack of due diligence and…
A Champix journal ad claimed significantly greater quit success vs NiQuitin patch. PMCPA ruled the claim misleading because the ad didn’t explain…
MHRA complained that a Zoladex (goserelin) journal ad referenced the MHRA. The Panel ruled this breached Clause 9.5 (no exemption applied). AstraZeneca…
A dispensing account manager sent an unapproved promotional Crestor email with inaccurate dosing and exaggerated efficacy/tolerability claims, plus unapproved slides and no…
A Times diabetes supplement funded and editorially controlled by Novo Nordisk included trial claims about unapproved liraglutide. The PMCPA ruled it promoted…
A Champix journal ad claimed significantly greater quit success vs an NRT patch. The PMCPA Panel ruled the claim misleading because the…
The MHRA complained that a Zoladex journal advertisement referenced the MHRA. The Panel ruled this breached Clause 9.5 because the MHRA had…
AstraZeneca self-reported an uncertified promotional email about Crestor sent to a dispensing practice. The email lacked prescribing information and included misleading, exaggerated…
AstraZeneca challenged a Novartis UK press release headline implying an overall survival benefit for Femara vs tamoxifen. The Panel ruled the headline…
A Times diabetes supplement funded and editorially controlled by Novo Nordisk included an interview describing liraglutide trial benefits. The PMCPA ruled this…
A Champix journal ad claimed significantly greater quit success vs NiQuitin CQ Clear at 12 weeks. The Panel ruled the claim misleading…
Our PMCPA rulings expert has knowledge of over 1,900 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.
